Viral Vectors for Vaccines and Gene Delivery

Posted on: 08/07/2019

KTN & UCL to host an event on Viral Vectors for Vaccines and Gene Delivery on 9th September in London.

Viral vectors for vaccine, and cell and gene therapy products have shown unprecedented clinical promise; however the manufacturing platforms for their commercial production are in their infancy when compared to therapeutic proteins. When analysing current process performance, major challenges emerge in both upstream and downstream operations: in USP the low titre and presence of large proportions of product-related impurities, in DSP low yields / loss of infectivity and the separation of product-related impurities. Furthermore, there is a need for advances in analytical capabilities in order to better understand viral vector products and critical quality attributes and to enable a Quality by Design philosophy.

This symposium will look at USP and DSP and the common analytical challenges across the major viral vector products. We will also seek to learn from other virus manufacturing processes e.g. those for flu vaccine.

This one-day meeting is open to all and offers a programme of invited talks, a poster session and an interactive

Confirmed speakers include:

  • Tony Hitchcock, Technical Director, Cobra Biologics
  • Simon McEwen, Head of Quality Assurance, Vaccines Manufacturing Innovation Centre (VMIC)
  • Ranna Patel, SF-IPV Technical Lead (MS&T), PTF UK Ltd


Register for the event now. 


The event has been organised by the Future Vaccine Manufacturing Research Hub (Vax-Hub), the Future Targeted Healthcare Manufacturing Hub and the Knowledge Transfer Network. Other Hub events can be viewed here.

Share this article


Connect with Innovate UK Business Connect

Join Innovate UK Business Connect's mailing list to receive updates on funding opportunities, events and to access Innovate UK Business Connect's deep expertise. Please check your email to confirm your subscription and select your area(s) of interest.